Amgen's Q3 2021 earnings call highlights continued strong performance, driven by volume growth and successful launches like LUMAKRAS.  Management expresses confidence in the long-term growth potential, particularly in the immunology and oncology sectors. The call points to significant opportunities in the pipelines with several first-in-class products and successful biosimilars. The expectation for favorable data in the first half of 2022 from ongoing clinical trials and updated guidance suggests a positive outlook for Amgenâ€™s stock price.
[1]
